世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ダーカムス病市場調査レポート:2030年までの予測


Dercums Disease Market Research Report Forecast till 2030

ダーカム病市場調査レポート:2030年までの予測 市場概要 ダーカム病市場は予測期間中にCAGR 6.76%を記録すると予測される。興味深い疾患の優勢が高まっており、研究および進歩の運動が拡大していることが市場... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Market Research Future
マーケットリサーチフューチャー (MRFR)
2023年11月1日 US$7,250
ライセンス・価格情報
注文方法はこちら
115 英語

 

サマリー

ダーカム病市場調査レポート:2030年までの予測
市場概要
ダーカム病市場は予測期間中にCAGR 6.76%を記録すると予測される。興味深い疾患の優勢が高まっており、研究および進歩の運動が拡大していることが市場発展の原動力となっています。
コロナウイルスの継続的な大流行と並んで、例えば色脂肪症や脂肪腫のような珍しい病気は、世界的に大きなウェイトを占めています。2021年2月に開催されたNCBIの調査によると、毎年およそ2500人の遊離結合(脂肪)組織疾患が見られ、そのほとんどが脂肪水腫、6人がFML-Type DD、10人が血管脂肪腫-Type Dercum病であった。さらに、同様のレビューによると、Dercum病の優位性は人口の0.64%であり、米国における脂肪水腫の一般性は女性の11%と考えられているが、その範囲は5〜39%である。ダルカム病患者の大部分は女性である。
その上、ダルカム病は脂性組織(脂肪腫)の様々な、苦痛を伴う発生によって描写される。このように、珍しい病気を経験する患者の数は普遍的に増加している。また、コロナウイルスの増加も同様に、ダーラム病の市場発展に根本的な影響を与える。このような疾患症例の増加は、ダーラム病に対する関心を世界的に拡大すると予想される。
市場セグメント
ダーキューム病の市場区分は、治療法に基づき、手術、投薬、脂肪吸引、電気治療、鍼治療、その他が含まれる。
ダーキュム病市場は、病院&クリニック、外来手術センター、その他を含むエンドユーザーに基づいてセグメント化されます。流通チャネルに基づくと、市場は病院薬局、小売薬局、その他に分けられる。
地域別インサイト

北米のダーキューム病市場は2022年に最大の市場シェアを占めた。これは、一般的でない疾患治療薬やガジェットの改良に向けた理想的な政府の行動や、同地域における投薬の承認が理由である。
また、ドイツ市場が最大の市場シェアを占めており、フランス市場はヨーロッパで最も急速に発展している市場である。
アジア太平洋地域の難病市場は、2023年から2030年にかけて重要な発展を遂げると考えられている。これは、アジア太平洋地域で脂肪性無色症を治療するための薬のための投機、臨床予備検査、組織の研究開発が増加しているためである。
その他の地域は、中東、アフリカ、ラテンアメリカに分けられる。先に述べた地域の皮膚萎縮性疾患市場は、おそらく組織によるこの地域への資産と関心の高まりによって発展が見られるだろう。

主要企業
ダルカム病市場の主要企業には、ファイザー(米国)、アッヴィ(米国)、ジョンソン・エンド・ジョンソン・サービス(米国)、グラクソ・スミスクライン(英国)、ボシュロム(カナダ)、カリウェイ(台湾)、ラジエル・セラピューティクス(イスラエル)、ニバルタ(米国)、BHRファーマシューティカルズ(英国)、ノバルティス(スイス)などがある。



ページTOPに戻る


目次

目次

1 エグゼクティブ・サマリー

2 市場紹介

2.1 定義

2.2 調査範囲

2.3 研究目的

2.4 前提条件と限界のリスト

3 調査方法

3.1 データマイニング

3.2 二次調査

3.3 一次調査

3.3.1 一次インタビューと情報収集プロセス

3.3.2 一次回答者の内訳

3.4 予想手法

3.5 市場規模推定のための調査手法

3.5.1 ボトムアップアプローチ

3.5.2 トップダウンアプローチ

3.6 データの三角測量

3.7 バリデーション

4 マーケットダイナミクス

4.1 概要

4.2 ドライバ

4.2.1 希少疾患の増加

4.2.2 研究開発活動の増加

4.3 制限

4.3.1 国民の病気に対する認識不足

4.4機会

4.4.1 戦略的イニシアチブの増加

5 市場要因分析

5.1 バリューチェーン分析

5.1.1 研究開発

5.1.2 製造

5.1.3 販売と流通

5.1.4 販売後のレビュー

5.2 ポーターの5力モデル

5.2.1 新規参入の脅威

5.2.2 供給者の交渉力

5.2.3 代替品の脅威

5.2.4 買い手の交渉力

5.2.5 ライバルの激しさ

5.3 Covid-19が世界のダーキューム病市場に与える影響

5.3.1 サプライチェーンへの影響

5.3.2 需要への影響

5.3.3 市場への影響

6 ダーカム病の世界市場、治療法別

6.1 概要

6.2 手術

6.3 薬物療法

6.3.1 利尿剤

6.3.2 非ステロイド性抗炎症薬

6.3.3 副腎皮質ステロイド

6.3.4 その他

6.4 脂肪吸着

6.5 電気療法

6.6 アキュパンクチャー

6.7 その他

7 ダーカム病の世界市場:エンドユーザー別

7.1 概要

7.2 病院・診療所

7.3 外来手術センター

7.4 その他

8 ダーカム病の世界市場:流通チャネル別

8.1 概要

8.2 病院薬局

8.3 小売薬局

8.4 その他

9 ダーカム病の世界市場、地域別

9.1 概要

9.2 北米

9.2.1 米国

9.2.2 カナダ

9.3 ヨーロッパ

9.3.1 ドイツ

9.3.2 イギリス

9.3.3 フランス

9.3.4 イタリア

9.3.5 スペイン

9.3.6 その他のヨーロッパ

9.4 アジア太平洋

9.4.1 中国

9.4.2 インド

9.4.3 インド

9.4.4 オーストラリア

9.4.5 韓国

9.4.6 その他のアジア太平洋地域

9.5 その他の地域

9.5.1 中東

9.5.2 アフリカ

9.5.3 ラテンアメリカ

10 競争環境

10.1 概要

10.2 競争ベンチマーク

10.3 財務マトリックス

10.3.1 売上高(百万米ドル)、2022年

10.3.2 研究開発費(百万米ドル)、2022年

11 会社プロファイル

11.1 ファイザー

11.1.1 会社概要

11.1.2 財務概要

11.1.3 提供製品

11.1.4 主要開発製品

11.1.5 swot分析

11.1.6 主要戦略

11.2 ABBVIE, INC

11.2.1 会社概要

11.2.2 財務概要

11.2.3 提供製品

11.2.4 主要開発製品

11.2.5 主要戦略

11.3 ジョンソン・エンド・ジョンソン・サービス株式会社

11.3.1 会社概要

11.3.2 財務概要

11.3.3 提供製品

11.3.4 主要開発製品

11.3.5 swot分析

11.3.6 主要戦略

11.4 グラクソスミスクラインPLC

11.4.1 会社概要

11.4.2 財務概要

11.4.3 提供製品

11.4.4 主要開発製品

11.4.5 swot分析

11.4.6 主要戦略

11.5 ボシュロム社

11.5.1 会社概要

11.5.2 財務概要

11.5.3 提供製品

11.5.4 主要開発製品

11.5.5 主要戦略

11.6 キャリウェイ

11.6.1 会社概要

11.6.2 財務概要

11.6.3 提供製品/サービス

11.6.4 主要開発

11.6.5 主要戦略

11.7 ラジール・セラピューティクス社

11.7.1 会社概要

11.7.2 財務概要

11.7.3 提供製品

11.7.4 主要開発製品

11.7.5 主要戦略

11.8 ニバルタ

11.8.1 会社概要

11.8.2 財務概要

11.8.3 提供製品

11.8.4 主要開発製品

11.8.5 swot分析

11.8.6 主要戦略

11.9 BHRファーマシューティカルズ

11.9.1 会社概要

11.9.2 財務概要

11.9.3 提供製品

11.9.4 主要戦略

11.10 ノバルティス

11.10.1 会社概要

11.10.2 財務概要

11.10.3 提供製品

11.10.4 主要開発製品

11.10.5 swot分析

11.10.6 主要戦略

12 付録

12.1 参考文献

12.2 関連レポート

ページTOPに戻る



図表リスト

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL: DERCUM’S DISEASE MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL: DERCUM’S DISEASE MARKET, FOR DIURETICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL: DERCUM’S DISEASE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL: DERCUM’S DISEASE MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL: DERCUM’S DISEASE MARKET, FOR LIPOSUCTION, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL: DERCUM’S DISEASE MARKET, FOR ELECTROTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL: DERCUM’S DISEASE MARKET, FOR ACUPUNCTURE, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: DERCUM’S DISEASE MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL: DERCUM’S DISEASE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 22 GLOBAL: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 28 US: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 29 US: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 30 US: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 31 US: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 32 CANADA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 33 CANADA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 34 CANADA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 35 CANADA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 36 EUROPE: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 37 EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 38 EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 39 EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 41 GERMANY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 42 GERMANY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 43 GERMANY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 44 GERMANY: DERCUM’S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2018–2030 (USD MILLION)

TABLE 45 UK: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 UK: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 47 UK: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 48 UK: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 49 FRANCE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 50 FRANCE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 51 FRANCE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 52 FRANCE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 53 ITALY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 54 ITALY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 55 ITALY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 56 ITALY: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 57 SPAIN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 58 SPAIN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 59 SPAIN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 60 SPAIN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 61 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 63 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 64 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 65 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 66 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 67 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 68 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 69 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 70 CHINA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 71 CHINA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 72 CHINA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 73 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 74 INDIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 75 INDIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 76 INDIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 77 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 78 JAPAN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 79 JAPAN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 80 JAPAN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 81 JAPAN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 82 AUSTRALIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 83 AUSTRALIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 84 AUSTRALIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 85 AUSTRALIA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 86 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 87 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 88 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 89 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 90 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 91 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 92 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 93 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 94 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030(USD MILLION)

TABLE 95 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 96 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 97 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 98 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 99 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 100 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 101 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 102 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 103 AFRICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 104 AFRICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 105 AFRICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 106 AFRICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 107 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 108 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 109 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 110 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 111 MAJOR PLAYERS IN THE GLOBAL DERCUM’S DISEASE MARKET

TABLE 112 PFIZER INC: PRODUCTS OFFERED

TABLE 113 ABBVIE, INC: PRODUCTS OFFERED

TABLE 114 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED

TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED

TABLE 116 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED

TABLE 117 3M: PRODUCTS/SERVICES OFFERED

TABLE 118 RAZIEL THERAPEUTICS LTD: PRODUCTS OFFERED

TABLE 119 NIVARTA, INC: PRODUCTS OFFERED

TABLE 120 BHR PHARMACEUTICALS LTD: PRODUCTS OFFERED

TABLE 121 NOVARTIS INTERNATIONAL AG: PRODUCTS OFFERED

 

ページTOPに戻る


 

Summary

Dercum’s Disease Market Research Report Forecast till 2030
Market Overview
The Dercum’s Disease Market is anticipated to register a CAGR of 6.76% during the forecast period. The rising predominance of interesting diseases and expanding research and advancement exercises are driving market development.
Uncommon diseases, for example, adiposis dolorosa, and lipomas alongside the continuous Coronavirus pandemic, represent a significant weight worldwide. As per the NCBI study, held in February 2021, roughly 2500 individuals each year with free connective (fat) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum's disease. Moreover, a similar review recommended that the predominance of Dercum's disease is 0.64% in the populace, and the commonness of lipedema in the USA is believed to be 11% in ladies however the reach is 5 to 39%. A greater part of individuals with dercum's disease are ladies.
Besides, dercum's disease is portrayed by various, agonizing developments of greasy tissue (lipomas). In this way, the quantity of patients experiencing uncommon diseases is expanding universally. Besides, the rising instances of Coronavirus likewise fundamentally affect the market development of the dercum's disease. Such an ascent in the quantity of diseases cases is expected to worldwide expand the interest for dercum's disease.
Market Segmentation
The Market segments of Dercum’s Disease, based on treatment, includes surgery, medication, liposuction, electrotherapy, acupuncture, and others.
The Dercum’s Disease Market segmentation is based on end user that includes hospital & clinics ambulatory surgical centers others. Based on distribution channel the market is divided into hospital pharmacies, retail pharmacies, and others.
Regional Insights

The North America dercum's disease market represented the biggest market share in 2022. This is because of the ideal government act towards for the improvement of uncommon disease drug and gadgets as well as endorsement of medication in the district.
Europe dercum's disease market represents the second-biggest market share because of the research concentrates on through medical services administrative bodies for the therapy of dercum's disease and ideal approach and public undertakings systems. further, the Germany market of dercum's disease was credited to hold the biggest market share, and the France market of dercum's disease is supposed to quickest developing market in the European locale.
The Asia-Pacific dercum's disease market is supposed to develop at a critical offer from 2023 to 2030. This is because of the rising speculation, clinical preliminary examinations, and organizations' Research and development for medications to treat fat dolorosa in the Asia-Pacific locale.
The Rest of the World is portioned into the Middle East, Africa, and Latin America. The market of dercum's disease in the previously mentioned locales is probably going to observe development because of raising of assets and interests in the area through organizations.

Major Players
Key Companies in the market of dercum’s disease include Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland).



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.4 FORECASTING TECHNIQUES

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.5.1 BOTTOM-UP APPROACH

3.5.2 TOP-DOWN APPROACH

3.6 DATA TRIANGULATION

3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING PREVALENCE OF RARE DISEASES

4.2.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS AMONG THE PEOPLE ABOUT THE DISEASE

4.4 OPPORTUNITIES

4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 SALES AND DISTRIBUTION

5.1.4 POST-SALES REVIEW

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL DERCUM’S DISEASE MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON DEMAND

5.3.3 IMPACT ON MARKET

6 GLOBAL DERCUM’S DISEASE MARKET, BY TREATMENT

6.1 OVERVIEW

6.2 SURGERY

6.3 MEDICATION

6.3.1 DIURETICS

6.3.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUG

6.3.3 CORTICOSTEROIDS

6.3.4 OTHERS

6.4 LIPOSUCTION

6.5 ELECTROTHERAPY

6.6 ACUPUNCTURE

6.7 OTHERS

7 GLOBAL DERCUM’S DISEASE MARKET, BY END-USER

7.1 OVERVIEW

7.2 HOSPITAL & CLINICS

7.3 AMBULATORY SURGICAL CENTERS

7.4 OTHERS

8 GLOBAL DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW

8.2 HOSPITAL PHARMACIES

8.3 RETAIL PHARMACIES

8.4 OTHERS

9 GLOBAL DERCUM’S DISEASE MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 INDIA

9.4.4 AUSTRALIA

9.4.5 SOUTH KOREA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 FINANCIAL MATRIX

10.3.1 SALES (USD MILLION), 2022

10.3.2 R&D EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

11.1 PFIZER INC

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 ABBVIE, INC

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 KEY STRATEGIES

11.3 JOHNSON & JOHNSON SERVICES, INC

11.3.1 COMPANY OVERVIEWS

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 SWOT ANALYSIS

11.3.6 KEY STRATEGIES

11.4 GLAXOSMITHKLINE PLC

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 BAUSCH & LOMB INCORPORATED

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTSS

11.5.5 KEY STRATEGIES

11.6 CALIWAY

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS/SERVICES OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 RAZIEL THERAPEUTICS LTD

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 KEY STRATEGIES

11.8 NIVARTA, INC.

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 BHR PHARMACEUTICALS LTD

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY STRATEGIES

11.10 NOVARTIS INTERNATIONAL AG

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 SWOT ANALYSIS

11.10.6 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

ページTOPに戻る



List of Tables/Graphs

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 3 GLOBAL: DERCUM’S DISEASE MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL: DERCUM’S DISEASE MARKET, FOR MEDICATION, BY TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL: DERCUM’S DISEASE MARKET, FOR DIURETICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL: DERCUM’S DISEASE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL: DERCUM’S DISEASE MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL: DERCUM’S DISEASE MARKET, FOR LIPOSUCTION, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL: DERCUM’S DISEASE MARKET, FOR ELECTROTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL: DERCUM’S DISEASE MARKET, FOR ACUPUNCTURE, BY REGION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL: DERCUM’S DISEASE MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL: DERCUM’S DISEASE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL: DERCUM’S DISEASE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 GLOBAL: DERCUM’S DISEASE MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 22 GLOBAL: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 23 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 26 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 28 US: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 29 US: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 30 US: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 31 US: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 32 CANADA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 33 CANADA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 34 CANADA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 35 CANADA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 36 EUROPE: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 37 EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 38 EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 39 EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 41 GERMANY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 42 GERMANY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 43 GERMANY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 44 GERMANY: DERCUM’S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2018–2030 (USD MILLION)

TABLE 45 UK: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 UK: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 47 UK: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 48 UK: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 49 FRANCE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 50 FRANCE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 51 FRANCE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 52 FRANCE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 53 ITALY: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 54 ITALY: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 55 ITALY: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 56 ITALY: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 57 SPAIN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 58 SPAIN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 59 SPAIN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 60 SPAIN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 61 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030 (USD MILLION)

TABLE 63 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030 (USD MILLION)

TABLE 64 REST OF EUROPE: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030 (USD MILLION)

TABLE 65 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 66 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 67 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 68 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 69 ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 70 CHINA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 71 CHINA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 72 CHINA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 73 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 74 INDIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 75 INDIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 76 INDIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 77 CHINA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 78 JAPAN: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 79 JAPAN: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 80 JAPAN: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 81 JAPAN: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 82 AUSTRALIA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 83 AUSTRALIA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 84 AUSTRALIA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 85 AUSTRALIA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 86 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 87 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 88 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 89 SOUTH KOREA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 90 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 91 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 92 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 93 REST OF ASIA PACIFIC: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 94 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY REGION, 2018–2030(USD MILLION)

TABLE 95 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 96 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 97 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 98 REST OF THE WORLD: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 99 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 100 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 101 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 102 MIDDLE EAST: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 103 AFRICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 104 AFRICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 105 AFRICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 106 AFRICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 107 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY TREATMENT, 2018–2030(USD MILLION)

TABLE 108 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY MEDICATION, 2018–2030(USD MILLION)

TABLE 109 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY END-USER, 2018–2030(USD MILLION)

TABLE 110 LATIN AMERICA: DERCUM’S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018–2030(USD MILLION)

TABLE 111 MAJOR PLAYERS IN THE GLOBAL DERCUM’S DISEASE MARKET

TABLE 112 PFIZER INC: PRODUCTS OFFERED

TABLE 113 ABBVIE, INC: PRODUCTS OFFERED

TABLE 114 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED

TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED

TABLE 116 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED

TABLE 117 3M: PRODUCTS/SERVICES OFFERED

TABLE 118 RAZIEL THERAPEUTICS LTD: PRODUCTS OFFERED

TABLE 119 NIVARTA, INC: PRODUCTS OFFERED

TABLE 120 BHR PHARMACEUTICALS LTD: PRODUCTS OFFERED

TABLE 121 NOVARTIS INTERNATIONAL AG: PRODUCTS OFFERED

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Market Research Future社の医療分野での最新刊レポート

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Market Research Future社はどのような調査会社ですか?


マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。   下記分野については、分野毎に専... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る